Skip to main content
SpringerLink
Log in

Emerging Role of the Pathologist in Precision Medicine for HCC

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.

    Article  Google Scholar 

  2. Heimbach J, Kulik LM, Finn R, et al. Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017;67:358–380.

    Article  Google Scholar 

  3. Hayashi PH, Trotter JF, Forman L, et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. Liver Transpl. 2004;10:42–48.

    Article  PubMed  Google Scholar 

  4. Joo I, Lee JM, Lee SM, Lee JS, Park JY, Han JK. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI. J Magn Reson Imaging. 2016;44:1330–1338.

    Article  PubMed  Google Scholar 

  5. Mueller C, Waldburger N, Stampfl U, et al. Non-invasive diagnosis of hepatocellular carcinoma revisited. Gut. 2017;67:991–993.

    Article  CAS  PubMed  Google Scholar 

  6. Mullhaupt B, Durand F, Roskams T, Dutkowski P, Heim M. Is tumor biopsy necessary? Liver Transpl. 2011;17:S14–S25.

    Article  PubMed  Google Scholar 

  7. Caturelli E, Solmi L, Anti M, et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut. 2004;53:1356–1362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology. 1998;28:323–331.

    Article  CAS  PubMed  Google Scholar 

  9. Torbenson M, Schirmacher P. Liver cancer biopsy–back to the future? Hepatology. 2015;61:431–433.

    Article  PubMed  Google Scholar 

  10. Maturen KE, Nghiem HV, Marrero JA, et al. Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. AJR Am J Roentgenol. 2006;187:1184–1187.

    Article  PubMed  Google Scholar 

  11. Bosman F, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010:1–417.

    Google Scholar 

  12. Saldarriaga J, Bisig B, Couchy G, et al. Focal beta-catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas. Histopathology. 2017;71:989–993.

    Article  PubMed  Google Scholar 

  13. Bioulac-Sage P, Sempoux C, Balabaud C. Hepatocellular adenoma: classification, variants and clinical relevance. Semin Diagn Pathol. 2017;34:112–125.

    Article  PubMed  Google Scholar 

  14. Roncalli M, Roz E, Coggi G, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology. 1999;30:1174–1178.

    Article  CAS  PubMed  Google Scholar 

  15. International Consensus Group for Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658–664.

    Article  Google Scholar 

  16. Theise ND, Curado MP, Franceschi S, et al. Hepatocellular carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2010:205–216.

    Google Scholar 

  17. Pilati C, Letouze E, Nault JC, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25:428–441.

    Article  CAS  PubMed  Google Scholar 

  18. Calderaro J, Couchy G, Imbeaud S, et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol. 2017;67:727–738.

    Article  CAS  PubMed  Google Scholar 

  19. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med. 2006;12:410–416.

    Article  CAS  PubMed  Google Scholar 

  20. Minguez B, Hoshida Y, Villanueva A, et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol. 2011;55:1325–1331.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Nault JC, De Reynies A, Villanueva A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145:176–187.

    Article  CAS  PubMed  Google Scholar 

  22. Pellegrino R, Calvisi DF, Neumann O, et al. EEF1A2 inactivates p53 by way of PI3 K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. Hepatology. 2014;59:1886–1899.

    Article  CAS  PubMed  Google Scholar 

  23. Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327–1341.

    Article  CAS  Google Scholar 

  24. Graham RP, Jin L, Knutson DL, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol. 2015;28:822–829.

    Article  CAS  PubMed  Google Scholar 

  25. Wood LD, Heaphy CM, Daniel HD, et al. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol. 2013;26:1586–1593.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Li T, Fan J, Qin LX, et al. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol. 2011;18:1955–1963.

    Article  CAS  PubMed  Google Scholar 

  27. Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin N Am. 2017;46:365–391.

    Article  Google Scholar 

  28. Nishi H, Taguchi K, Asayama Y, et al. Sarcomatous hepatocellular carcinoma: a special reference to ordinary hepatocellular carcinoma. J Gastroenterol Hepatol. 2003;18:415–423.

    Article  PubMed  Google Scholar 

  29. Matsuura S, Aishima S, Taguchi K, et al. ‘Scirrhous’ type hepatocellular carcinomas: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology. 2005;47:382–390.

    Article  CAS  PubMed  Google Scholar 

  30. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol. 2010;34:1630–1636.

    PubMed  Google Scholar 

  31. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.

    Article  Google Scholar 

  32. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290–2300.

    Article  CAS  PubMed  Google Scholar 

  33. Horwitz E, Stein I, Andreozzi M, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov. 2014;4:730–743.

    Article  CAS  PubMed  Google Scholar 

  34. Rudalska R, Dauch D, Longerich T, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med. 2014;20:1138–1146.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940–952.

    Article  PubMed  Google Scholar 

  37. Zhu AX, Baron AD, Malfertheiner P, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of reach trial results by child-pugh score. JAMA Oncol. 2016;3:235–243.

    Article  Google Scholar 

  38. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.

    Article  CAS  PubMed  Google Scholar 

  39. Leichsenring J, Volckmar AL, Kirchner M, et al. Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. Genes Chromosomes Cancer. 2018;57:70–79.

    Article  CAS  PubMed  Google Scholar 

  40. Allgauer M, Budczies J, Christopoulos P, et al. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. Transl Lung Cancer Res. 2018;7:703–715.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J Hepatol. 2015;62:1420–1429.

    Article  CAS  PubMed  Google Scholar 

  42. Brunner SM, Itzel T, Rubner C, et al. Tumor-infiltrating B cells producing antitumor active immunoglobulins in resected HCC prolong patient survival. Oncotarget. 2017;8:71002–71011.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169:1342–1356.

    Article  CAS  PubMed  Google Scholar 

  44. Bodenmiller B. Multiplexed epitope-based tissue imaging for discovery and healthcare applications. Cell Syst. 2016;2:225–238.

    Article  CAS  PubMed  Google Scholar 

  45. Campbell BB, Light N, Fabrizio D, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171:1042–1056.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–2501.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany

    Thomas Longerich & Peter Schirmacher

Authors
  1. Thomas Longerich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Schirmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Longerich.

Ethics declarations

Conflict of interest

The author declares that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Longerich, T., Schirmacher, P. Emerging Role of the Pathologist in Precision Medicine for HCC. Dig Dis Sci 64, 928–933 (2019). https://doi.org/10.1007/s10620-019-05548-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05548-z

Search

Navigation